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I. INTRODUCTION
Over the past twenty years, physicians have carried out bone marrow trans-
plants with increasing success.1 As the procedure gains in acceptance and avail-
ability over the coming years, our nation will be faced with important policy
choices regarding the regulation of bone marrow transplantation.
This essay begins with a brief recitation of the biology of bone marrow
transplantation, a description of the risks involved, and an introduction to the
National Marrow Donor Program. The focus of the essay then shifts to a policy
analysis of how the Food and Drug Administration (FDA) should regulate bone
marrow transplantation. Overriding considerations are protection of the public
health and eciency in implementing new regulations. An eective regulatory
scheme should ensure minimum protections for marrow recipients and donors
without signicantly impacting the resources of reguldted parties or FDA itself.
1H.G. DEEG, A GUIDE TO BONE MARROW TRANsPLANTATION,
preface (1988).
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1A. Biology of bone marrow and bone marrow transplan-
tation
As producer of the body's blood, healthy bone marrow is necessary for hu-
man life.2 Unfortunately, bone marrow is extremely sensitive to toxins and
drugs.3 For example, leukemia patients treated with chemoradiotherapy may
subsequently require bone marrow transplantation.4 Bone marrow transplanta-
tion may also be used to cure other malignancies and some hereditary diseases.5
The two main forms of bone marrow transplantation are autologous and
allogeneic.6 The more common form is autologous bone marrow transplantation,7
in which the patient's own marrow is stored, sometimes treated, and then re-
turned to the patient.8 Allogenic bone marrow transplantation involves trans-
planting bone marrow from a
2 ~ELI~ MARGET, LIFE'S BLOOD 21 (1992)
3.rd.
4DEEG, supra note 1, at preface.
5MARGET, supra note 2, at 13.
6Jacob M. Rowe, et. al., Recommended Guidelines for the
Management of Autologous and Allogeneic Bone Marrow
Transplantation: A Report from the Eastern Cooperative
Oncology Group (ECOG), 120 ANNALS OF INTERNAL MED. 143, 143
(1994)
7.
8See 57 Fed. Reg. 24,797, 24,803 (June 11, 1992)
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2donor to a recipient who suers from a marrow deciency or defect.9
B. Risks of bone marrow transplantation
The risks of bone marrow transplantation are extreme. For example, inade-
quately purging the bone marrow of a cancer patient undergoing an autologous
bone marrow transplant can result in relapse of the cancer.10 The recipient of
an allogeneic bone marrow transplant faces the risk of contracting an infectious
disease such as Acquired Immune Deciency Syndrome (AIDS).1~ In addition,
a recipient faces the risk of graft-versus-host disease (GVHD), which can be
fatal 12
GVHD results when cells derived from the immune system of the donor
attack cells of the recipient.13 Successful bone marrow transplantation requires
close matching of a particular gene, or HLA matching.~4 Because HLA type is
an inherited characteristic,15 a marrow transplant from one
9.
10See Ralph 0. Wallerstein, Jr. and Albert B. Deisseroth, Bone
Marrow Dysfunction in the Cancer Patient in CANCER: PRINCIPLES
AND PRAcTIcE OF ONCOLOGY 2262, 2272 (4th ed. 1993)
11National Marrow Donor Program Standards 4.122 (11th ed., adopted 10/28/94)
[hereinafter NMDP Standards]
12 ~GET, supra note 2, at 33.
13DEEG, supra note 1, at 191.
14See e.g., CURRENT MEDICAL DIAGNOSIS & TREATMENT 627 (Lawrence
M.
Tierney, Jr. et. al. eds., 1993).
15NATIONAL MARROW DONOR PROGRAM, REPORT TO OUR COM-
MUNITIES 1 (1994) [hereinafter NATIONAL MARROW DONOR PROGRAM
REPORT]
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3identical twin to another will almost certainly not result in GVHD.16 Pa-
tients in need of an allogeneic marrow transplant may sometimes nd a suf-
cient ELA match in another close relative such as a non-identical sibling.17
Unfortunately, however, only twenty to thirty percent of patients in need of an
allogeneic marrow transplant have an HLA-matching relative.18 The National
Marrow Donor Program assists patients in searching for nonrelated marrow
donors, as will be discussed in the following Section.
Although donation by a prospective donor with existing health conditions
may constitute a major physical risk to that donor, the risk of a serious com-
plication in a healthy donor is negligible.19 All donors, however, face minor
physical risks. For example, the procedure by which marrow is withdrawn from
the pelvis can be painful.20 In addition, the donor may be fatigued for up to
several weeks while the donor's marrow regenerates.21
l6 ~.A~GET, supra note 2, at 32.
17See DEEG, supra note 1, at preface.
18Nancy A. Kernan, et. al., Analysis of 462 Transplantations from Unrelated
Donors Facilitated by the National Marrow Donor Program, 328 NEw ENG. J.
MED. 593, 593 (1993)
19MARGET, supra note 2, at 36.
201d
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4C. National Marrow Donor Program
In 1986, Congress established the National Marrow Donor Program (NMDP)
to facilitate the matiching of potential recipients with nonrelated donors.22 Dur-
ing the program's rst four years, 462 patients received marrow transplants
from unrelated donors.23 In 1993, NMDP celebrated the enlistment of the one
millionth volunteer donor on the registry.24 Because of this success in recruiting
volunteers, fty-six percent of potential recipients nd a perfectly HLA-matched
donor.25 NMDP plans to continue to expand the registry so that more patients
in need of marrow will be able to nd HLA-matching donors.26
In addition to the donor registry, Congress directed NMDP to establish
criteria for those centers participating in the program, including marrow donor
centers, marrow collection centers, and marrow transplant centers.27 Among
other requirements, these standards must include:
(1) quality standards and standards for tissue
typing, obtaining the informed consent of donors, and
providing patient advocacy;
(2) donor selection criteria, based on established medical criteria1
to protect both the donor and the
2242 U.S.C. x 274k. See also Kernan, supra note 18, at 593.
23Kernan, supra note 18, at 593.
24NATIONAL MARROW DONOR PROGRAM REPORT, supra note 15,
at preface.
251d at 1.
26See id.
2742 U.S.C. x 247k(c).
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5recipient and to prevent the transmission of potentially harmful infectious
diseases such as the viruses that cause hepatitis and the etiologic agent for
Acquired Immune Deciency Syndrome.
(3) procedures to ensure the proper collection and transportation of
the marrow.... 28
NMDP established a set of standards which are now in their Eleventh Edition.29
Since these standards apply only to centers participating in NMDP, however,
centers which do not participate in NMDP are not regulated at all. The remain-
der of this essay considers whether FDA should regulate bone marrow centers,
and if so, how should those regulations should be implemented.
II. POLICY ANALYSIS
A. Although FDA regulation of bone marrow transplan-
tation may not have been necessary or even desirable in the past,
FDA regulation will become increasingly important as the number of
bone marrow centers grows.
As long as the number of bone marrow centers is limited, as it is today)'~
self-regulation ofd bone marrow centers is possible. The techniques of bone
marrow transplantation were developed by highly-trained researchers in high-
prole, established institutions. As bone marrow transplantation
281d
29 ~ ~ ~p Standards, supra note 11.
30See infra text accompanying note 36.
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6becomes more widespread, however, the quality of physician performing the
transplant may become more variable. FDA regulations would ensure that bone
marrow centers are directed by experienced and competent physicians.
There may not have been a need for regulation when bone marrow trans-
plantation was in its infancy, and indeed regulation at that time may have
stripped research facilities of the exibility to develop new techniques. While
research facilities should continue to be given enough exibility to develop new
techniques, in general bone marrow centers should follow accepted standards
for bone marrow transplantation. This will ensure some minimal level of safety
for all bone marrow recipients and donors.
B. The cost of failing to regulate is greater than the cost of
regulating.
The human and nancial costs of unsafe methods of bone marrow trans-
plantation are high. On the human side, for example, improper screening of
donors or improper purging of marrow intended for autologous transplantation
can result in death, imposing obvious human costs to patients and their loved
ones. Financial costs are also high. For example, improper screening of donors
may result in the transmission of infectious diseases, thus increasing health care
costs. The human and nancial costs of such tragedies are far greater than the
cost of setting standards, certifying centers, and mandating regular inspections
to assure compliance.
ID# 904|03-710
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7C. FDA should regulate bone marrow centers as soon as
possible.
Early regulation of bone marrow centers is more ecient than imposing a
regulatory structure once bone marrow centers have proliferated. The example
of the regulation of blood banks is instructive. In the late 1950's there were
fewer than blood banks and the regulatory climate was somewhat relaxed.31
In 1972 the Secretary of Health, Education, and Welfare transferred regulatory
control over the blood banks from the Division of Biological Standards to FDA.32
In 1973 FDA determined that all blood banks, including transfusion services,
would be considered drug manufacturers.33 As such, each facility { of which there
were now 7,000 { would have to register with FDA and comply with applicable
laws.34 The regulatory burden on FDA was enormous.35 The burden on the
regulated facilities was great as well. Had the FDA regulatory scheme been in
place twenty-ve years earlier, each facility would have registered and complied
with applicable laws from its conception. Compliance with the laws would have
been integrated into the opening of the facilities and therefore would not have
been
31J.M. Solomon, The Evolution of the Current Blood Banking Regulatory
Climate, 34 TRANSFUSION 272, 273 (1994)
321d at 274.
33.rd.
34Id.
35Id.
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8as burdensome. Likewise, the burden on the government would have been
spread out over time and would therefore have been much more manageable.
In 1988 there were between fty and one hundred universities and hospitals
in the United States performing bone marrow transplants)6 The number of bone
marrow centers is expected to increase dramatically. Regulations should be in
place so that FDA and the regulated entities are not forced suddenly to cope
with regulations which, had they been in place before the proliferation of bone
marrow centers, would not have been unreasonably burdensome.
D. Establishing basic standards of care will allow contin-
ued progress in learning about bone marrow transplantation.
Considerable progress has been made in learning to perform bone marrow
transplants, but much remains to be discovered about preventing the trans-
mission of infectious diseases and preventing graft-versus-host disease. Stan-
dardized care will allow for the integration of data from bone marrow centers
throughout the country,37 thus allowing researchers to dene better methods
for bone marrow transplantation .~
36DEEG, supra note 1, at 15.
37Rowe, supra note 6, at 143.
381d
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9Acknowledging the need for uniform criteria, several organizations have come
forward with their own proposals. These organizations include the Eastern
Cooperative Oncology Group39 and the American Society of Clinical Oncology,
which published criteria together with the American Society of HematologyA~3
Though the medical community acknowledges the need for uniform standards,
it is unlikely that the various groups will come together, along with NMDP, to
establish such standards. FDA can facilitate the process by holding hearings at
which the various groups can debate the parameters of sensible standards.
E. FDA regulation should ensure that potential donors and
recipients understand the risks involved and can make informed choices.
FDA regulations should mandate disclosure of risks to recipients and donors
and should allow both recipients and donors to make their own decisions re-
garding whether or not to participate in a transplant. Imagine, for example, a
patient who is dying of leukemia and is in need of an allogeneic bone marrow
transplant. This patient is one of the twenty to thirty percent41 of patients who
does not have an HLA-matched sibling donor. Registry searches uncover two
~The American Society of Clinical Oncology and American
Society of Hematology Recommended Criteria for the
Performance of Bone Marrow Transplantation, 8 J. CLINICAL
ONCOLOGY 563 (1990)
41Kernan, supra note 18, at 593.
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10potential donors. One is a perfect imA match but carries an infectious
disease. The other is free of infectious diseases but the HLA match is less then
perfect. Although FDA regulations may counsel against a transplant involving
either of these donors, ultimately the decision should remain with the patient.42
Although current NNDP standards aord a potential recipient wide latitude
in making informed choicesA3 they do not oer potential donors the same degree
of freedom regarding whether or not to proceed with donation. According to
the NMDP standards, The donor center medical director, the collection center
medical director, or the [potential donor's] examining physician... may deter-
mine that abnormal ndings [discovered during the medical examination of the
potential donor] constitute unacceptable risk(s) to the donor.~ Thus, suppose
a potential donor is a perfect match for a potential recipient. Suppose further
that this donor is the only person on the registry with a suitable HLA match.
A physician, not the donor, would make the nal decision regarding whether or
not the donation should take place. A better solution would be for the physician
to appraise the potential donor of the risks involved and let him make his own
decision regarding whether or not to proceed.
42Presumably there will be dicult insurance issues involved as well, but
that is beyond the scope of this essay.
43NMDP Standards, supra note 29, at 9.421. MId. at 9.310.
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11FDA regulations should ensure that the donor is not pressured into proceed-
ing with the bone marrow donation. Current NMDP standards mandate the
availability of a disinterested Donor Advocate to counsel the potential donor
about the risks of donating.45 FDA regulations should likewise mandate the
availability of such an advocate, particularly if the FDA regulations allow the
potential donor greater latitude to determine for himself whether or not to pro-
ceed with donation at considerable risk to himself.
F. FDA regulations should enhance fair competition among
bone marrow centers.
Maintaining minimal standards is important not only for the health of recipi-
ents and donors, but also for the economic well-being of bone marrow transplant
centers. As discussed in Section A of this Part, quality control from within the
medical community will become increasingly dicult as the number of bone
marrow centers increases. Without rugulations, bone marrow centers which cut
costs by circumventing minimal standards will be able to provide services at a
lower cost, yet consumers will not be aware of the substandard quality of care.
Reliable bone marrow centers would benet by FDA regulation because these
centers would not be undercut by centers with lower standards.
Minimal standards should enhance fair competition, not restrict competi-
tion. In other words, regulations should not
'~5Id. at 7.000.
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12be so burdensome that small bone marrow centers are unable to open and
operate. FDA should protect the public health, but it should do so in a sensible
manner which does not restrict the availability or raise the cost of bone marrow
transplantation.
G. FDA should regulate process as well as product.
The process by which bone marrow is extracted, treated, and transplanted
should be regulated for several reasons. First, in contrast to drugs created in
a labs, assessing the quality and safety of material which is derived from an
organism is extremely dicult ~ Second, bone marrow is not stored for a long
enough period of time to enable testing of the bone marrow itself. For example,
marrow intended for an allogeneic transplant is infused the same day as it is
harvested ~
These policy considerations suggest that FDA should regulate bone marrow
as a biological product rather than as a drug, because only if bone marrow
is regulated as a biological product will FDA have authority to license bone
marrow establishments as well as to license the product itself A8 In this way,
FDA can assure the integrity of bone
~See David A. Kessler, et. al., Regulation of Somatic-Cell Therapy and Gene
Therapy by the Food and Drug Administration, 329 NEw E1'~c. J. MED. 1169,
1171 (1993)
47wallerstein, supra note 10, at 2271.
~For an excellent discussion of FDA's legal authority to regulate human or-
gan transplants as drugs, medical devices, or biological products, see Statement
by the Food and Drug Administration Concerning its Legal Authority to Regulate
ID# 904|03|710
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13I
marrow by regulating the processes by which it is procured, treated, and
transplanted.
H. FDA should implement new regulations without dis-
rupting the ongoing availability of bone marrow transplantation.
During the development of any new licensing scheme, policymakers are faced
with the question of retroactivity. For example, following the thalidomide
tragedy, Congress passed the Drug Amendments of 1962.~~ Under these Amend-
ments, FDA was required to determine armatively that new drugs were safe
and eective.~ FDA was given four years in which to approve drugs that had
become available after 1938 but before the 1962 Amendments.51 The Amend-
ments grandfathered any drug that was available before 1938.52 This example
illustrates some of the possibilities available to FDA in implementing new bone
marrow regulations.
Bone marrow transplantation has saved many lives. To take it o the market
while FDA approves it would be heartless. On the other hand, grandfathering
existing bone marrow centers would not give FDA the degree of control it
Human Organ Transplants and to Prohibit their Sale: Hearing
Before the Subcommittee on Investigations and Oversight,
House Cornnu.ttee on Science and Technology, 98th Cong., 1st
Sess. (1983), reprinted in PETER BARTON HU'rr & RICHARD A.
MERRILL, FOOD AND DRUG LAW 693 (2d ed. 1991)
49HUTT, supra note 47, at 478.
~Id.
51Id
52Id
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14should exercise over these centers. A reasonable compromise would be sim-
ilar to the one reached in the approval of new drugs. All new bone marrow
centers would have to be licensed by FDA. Existing centers would have to be
licensed within a specic time frame, but could continue to operate as usual in
the meantime.
An alternative procedure for implementing new bone marrow regulations
would be for FDA formally to promulgate regulations requiring the licensing of
all establishments but tacitly to allow existing centers to continue their work
without scrutiny. For two reasons, however, FDA should not pursue such a
policy. The rst reason is a legal one. In Heckler v. Chaney the Supreme
Court held that FDA refusal to take enforcement steps is presumptively not
reviewable~ Chaney left open the question, however, of whether an agency's
rules might under certain circumstances provide courts with adequate guidelines
for informed judicial review of decisions.~ At least one court has determined that
this reservation, along with the basic tenet of administrative law that an agency
is bound to follow its own regulations, rendered FDA inaction reviewable despite
Chaney.55 Thus, FDA would face some risk that failure to enforce regulations
against existing centers would be reviewable. The risk of
~~470 U.S. 821, 831 (1985)
54Id. at 836.
55Heterochemical Corp. v. Food and Drug Admin., 664 F. Supp.
271, 274 (E.D.N.Y. 1986)
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15such an outcome is slight, however. A better reason for not pursuing this ap-
proach is that as a matter of policy, agencies should attempt to be as forthright
as possible. Being forthright helps regulated parties to plan and fosters con-
dence that FDA is at least trying to be fair and well-reasoned.
III. CONCLUSION
Government regulation of bone marrow transplantation would protect the
public health while at the same time creating a level playing eld among bone
marrow centers. Because of its experience regulating blood,~ FDA is the most
reasonable candidate to promulgate and enforce such regulations. According to
Craig W.S. Howe, chief executive ocer of NMDP, it is only a matter of time
before FDA starts regulating bone marrow.57 FDA should begin the regulation
process now, before a crisis and before bone marrow centers proliferate. In ad-
dition, FDA should take a well-reasoned approach to regulation of bone marrow
centers so that its eorts to protect the public health do not inadvertently injure
the public health by decreasing the availability or increasing the cost of bone
marrow transplantation.
565ee generally Solomon, supra note 31 (tracing the evolution of the current
blood banking regulatory climate). 57Personal communication (Jan. 11, 1995)
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